Physician profile
Ryan Almeida
NPI 1225250335
$13,515.93
in general payments reported to CMS, 2019-2025
25 companies · $1,837 in 2025
The $1,837 reported for 2025 was more than what 76% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,378 · 2020: $578 · 2021: $1,339 · 2022: $904 · 2023: $946 · 2024: $1,534 · 2025: $1,837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,316.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $7,048.23 | 2019-2024 | Senza |
| Abbott Laboratories | $2,332.42 | 2020-2025 | Proclaim, Eterna, Prodigy |
| Boston Scientific Corporation | $1,982.26 | 2020-2025 | Infinion 16, Wavewriter Alpha Prime 16, Infinion 16 |
| Vertiflex, INC. | $693.16 | 2019 | |
| Collegium Pharmaceutical, INC. | $314.75 | 2020-2025 | Belbuca, Xtampza |
| Medtronic, INC. | $200.25 | 2022-2024 | Intellis Adaptivestim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $193.29 | 2020-2024 | Relistor |
| Biodelivery Sciences International, INC. | $133.21 | 2020-2021 | |
| Saluda Medical Americas, INC. | $96.90 | 2025 | Evoke |
| Forte Bio-Pharma LLC | $83.09 | 2024-2025 | Prolate, Nalocet, Tanlor |
| Abbvie INC. | $75.83 | 2022-2024 | |
| Vertex Pharmaceuticals Incorporated | $55.12 | 2024-2025 | |
| Si-Bone, INC. | $45.27 | 2024 | |
| Mml US, INC. | $36.84 | 2025 | Reactiv8 |
| Supernus Pharmaceuticals, INC. | $31.57 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $29.63 | 2025 | Senza |
| Scilex Pharmaceuticals INC. | $20.85 | 2020 | |
| Redhill Biopharma INC. | $20.75 | 2020 | |
| Amgen INC. | $20.73 | 2021 | |
| Virtus Pharmaceuticals LLC | $19.98 | 2023 | Levorphanol Tartrate |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.01 | 2022 | |
| Axsome Therapeutics, INC. | $17.40 | 2025 | Symbravo |
| Depuy Synthes Sales INC. | $17.07 | 2024 | Monovisc |
| Orexo US, INC. | $15.03 | 2022 | |
| Neuronetics, INC. | $14.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Almeida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.